Skip to main content

Articles

Page 1 of 38

  1. Authors: Arnon Nagler, Myriam Labopin, Didier Blaise, Anna Maria Raiola, Lucia Lopez Corral, Stefania Bramanti, Simona Sica, Mi Kwon, Yener Koc, Jiri Pavlu, Alexander Kulagin, Alessandro Busca, Arancha Bermúdez Rodríguez, Péter Reményi, Christoph Schmid, Eolia Brissot…
    Citation: Journal of Hematology & Oncology 2023 16:106
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2023 16:58

  3. Diagnosing post-transplant lymphoproliferative disorder (PTLD) is challenging and often requires invasive procedures. Analyses of cell-free DNA (cfDNA) isolated from plasma is minimally invasive and highly eff...

    Authors: Nick Veltmaat, Yujie Zhong, Filipe Montes de Jesus, Geok Wee Tan, Johanna A. A. Bult, Martijn M. Terpstra, Pim G. N. J. Mutsaers, Wendy B. C. Stevens, Rogier Mous, Joost S. P. Vermaat, Martine E. D. Chamuleau, Walter Noordzij, Erik A. M. Verschuuren, Klaas Kok, Joost L. Kluiver, Arjan Diepstra…
    Citation: Journal of Hematology & Oncology 2023 16:104
    Content type: Correspondence Published on:

  4. Lipid metabolic reprogramming is an emerging hallmark of cancer. In order to sustain uncontrolled proliferation and survive in unfavorable environments that lack oxygen and nutrients, tumor cells undergo metab...

    Authors: Hao-Ran Jin, Jin Wang, Zi-Jing Wang, Ming-Jia Xi, Bi-Han Xia, Kai Deng and Jin-Lin Yang
    Citation: Journal of Hematology & Oncology 2023 16:103
    Content type: Review Published on:

  5. Pancreatic cancer lacks effective therapy. Here, we reported two metastatic pancreatic cancer patients administrated with Claudin 18.2 (CLDN 18.2) CART therapy after the failure of standard therapy (NCT0458147...

    Authors: Changsong Qi, Tong Xie, Jun Zhou, Xicheng Wang, Jifang Gong, Xiaotian Zhang, Jian Li, Jiajia Yuan, Chang Liu and Lin Shen
    Citation: Journal of Hematology & Oncology 2023 16:102
    Content type: Correspondence Published on:

  6. In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted therapies. However, not all cancer ...

    Authors: Letong Cai, Yuchen Li, Jiaxiong Tan, Ling Xu and Yangqiu Li
    Citation: Journal of Hematology & Oncology 2023 16:101
    Content type: Review Published on:

  7. Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2 (HER2). Altho...

    Authors: Shuangli Zhu, Yuze Wu, Bin Song, Ming Yi, Yuheng Yan, Qi Mei and Kongming Wu
    Citation: Journal of Hematology & Oncology 2023 16:100
    Content type: Review Published on:

  8. Mantle cell lymphoma is a B cell non-Hodgkin lymphoma (NHL), representing 2–6% of all NHLs and characterized by overexpression of cyclin D1. The last decade has seen the development of many novel treatment app...

    Authors: Neeraj Jain, Mukesh Mamgain, Sayan Mullick Chowdhury, Udita Jindal, Isha Sharma, Lalit Sehgal and Narendranath Epperla
    Citation: Journal of Hematology & Oncology 2023 16:99
    Content type: Review Published on:

  9. Cancers are a group of heterogeneous diseases characterized by the acquisition of functional capabilities during the transition from a normal to a neoplastic state. Powerful experimental and computational tool...

    Authors: Dezhi Huang, Naya Ma, Xinlei Li, Yang Gou, Yishuo Duan, Bangdong Liu, Jing Xia, Xianlan Zhao, Xiaoqi Wang, Qiong Li, Jun Rao and Xi Zhang
    Citation: Journal of Hematology & Oncology 2023 16:98
    Content type: Review Published on:

  10. Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and chimeric antigen receptor (C...

    Authors: Pengchao Zhang, Guizhong Zhang and Xiaochun Wan
    Citation: Journal of Hematology & Oncology 2023 16:97
    Content type: Review Published on:

  11. About half of AML patients achieving complete remission (CR) display measurable residual disease (MRD) and eventually relapse. FLYSYN is an Fc-optimized antibody for eradication of MRD directed to FLT3/CD135, ...

    Authors: Jonas S. Heitmann, Richard F. Schlenk, Daniela Dörfel, Sabine Kayser, Konstanze Döhner, Michael Heuser, Felicitas Thol, Silke Kapp-Schwoerer, Jannik Labrenz, Dominic Edelmann, Melanie Märklin, Wichard Vogel, Wolfgang Bethge, Juliane S. Walz, Ludger Große-Hovest, Martin Steiner…
    Citation: Journal of Hematology & Oncology 2023 16:96
    Content type: Research Published on:

  13. Recently, therapeutic antibodies against programmed cell death 1 (PD-1) and its ligand (PD-L1) have exerted potent anticancer effect in a variety of tumors. However, blocking the PD-1/PD-L1 axis alone is not s...

    Authors: Mengke Niu, Ming Yi, Yuze Wu, Lijuan Lyu, Qing He, Rui Yang, Liang Zeng, Jian Shi, Jing Zhang, Pengfei Zhou, Tingting Zhang, Qi Mei, Qian Chu and Kongming Wu
    Citation: Journal of Hematology & Oncology 2023 16:94
    Content type: Research Published on:

  14. Immunotherapy has revolutionized cancer treatment, but currently, immuno-oncology agents have not been approved for patients with soft tissue sarcomas. However, there is growing evidence suggesting that immuno...

    Authors: Matthieu Roulleaux-Dugage and Antoine Italiano
    Citation: Journal of Hematology & Oncology 2023 16:93
    Content type: Editorial Published on:

  15. Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients. Teclistamab was approved for relapsed/refractory MM therapy...

    Authors: Juanjuan Zhao, Quan Ren, Xinyuan Liu, Xiangqian Guo and Yongping Song
    Citation: Journal of Hematology & Oncology 2023 16:92
    Content type: Correspondence Published on:

  16. TP53 mutations (TP53MT) occur in diverse genomic configurations. Particularly, biallelic inactivation is associated with poor overall survival in cancer. Lesions affecting only one allele might not be directly le...

    Authors: Waled Bahaj, Tariq Kewan, Carmelo Gurnari, Arda Durmaz, Ben Ponvilawan, Ishani Pandit, Yasuo Kubota, Olisaemeka D. Ogbue, Misam Zawit, Yazan Madanat, Taha Bat, Suresh K. Balasubramanian, Hussein Awada, Ramsha Ahmed, Minako Mori, Manja Meggendorfer…
    Citation: Journal of Hematology & Oncology 2023 16:91
    Content type: Research Published on:

  17. Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 × CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to...

    Authors: Xinyuan Liu, Juanjuan Zhao, Xiangqian Guo and Yongping Song
    Citation: Journal of Hematology & Oncology 2023 16:90
    Content type: Correspondence Published on:

  19. BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side effects that can lengthen hospital stays and increase ...

    Authors: Kai Rejeski, Doris K. Hansen, Radhika Bansal, Pierre Sesques, Sikander Ailawadhi, Jennifer M. Logue, Eva Bräunlein, David M. Cordas dos Santos, Ciara L. Freeman, Melissa Alsina, Sebastian Theurich, Yucai Wang, Angela M. Krackhardt, Frederick L. Locke, Emmanuel Bachy, Michael D. Jain…
    Citation: Journal of Hematology & Oncology 2023 16:88
    Content type: Research Published on:

  20. NEDDylation, a post-translational modification through three-step enzymatic cascades, plays crucial roles in the regulation of diverse biological processes. NEDD8-activating enzyme (NAE) as the only activation...

    Authors: Dong-Jun Fu and Ting Wang
    Citation: Journal of Hematology & Oncology 2023 16:87
    Content type: Review Published on:

  21. Treatment of relapsed and/or refractory multiple myeloma (RRMM) utilizing the novel therapeutic target of the B-cell maturation antigen (BCMA) has demonstrated incredible results, leading to regulatory approva...

    Authors: James F. Wu and Binod Dhakal
    Citation: Journal of Hematology & Oncology 2023 16:86
    Content type: Correspondence Published on:

  22. Antibody–drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to their precise and powerful effect, they have become a new hotspot and an important trend in the ...

    Authors: Jiazheng Yu, Siyu Wu, Rong Li, Yuanhong Jiang, Jianyi Zheng, Zeyu Li, Mingyang Li, Kerong Xin, Xiaojiao Guan, Shijie Li and Xiaonan Chen
    Citation: Journal of Hematology & Oncology 2023 16:85
    Content type: Correspondence Published on:

  23. Hyperhomocysteinemia (HHcy) is closely associated with thrombotic diseases such as myocardial infarction and stroke. Enhanced platelet activation was observed in animals and humans with HHcy. However, the infl...

    Authors: Wenjing Lei, Zhuoliang Liu, Zhiyuan Su, Panpan Meng, Chun Zhou, Xiaomei Chen, Zheng Hu, An Xiao, Miaomiao Zhou, Liping Huang, Yiyue Zhang, Xianhui Qin, Junping Wang, Fengxin Zhu and Jing Nie
    Citation: Journal of Hematology & Oncology 2023 16:84
    Content type: Correspondence Published on:

  25. Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, anemia, extramedullary hematopoiesis, and splenomegaly. Patients with MF are at risk for reduced survival vers...

    Authors: Srdan Verstovsek, Ruben A. Mesa, Robert A. Livingston, Wilson Hu and John Mascarenhas
    Citation: Journal of Hematology & Oncology 2023 16:82
    Content type: Review Published on:

  26. Authors: N. Lopez-Muñoz, G. Hernández-Ibarburu, R. Alonso, J. M. Sanchez-Pina, R. Ayala, M. Calbacho, C. Cuellar, M. T. Cedena, A. Jiménez-Ubieto, R. Iñiguez, M. Pedrera, J. Cruz, L. Meloni, D. Pérez-Rey, P. Serrano, J. de la Cruz…
    Citation: Journal of Hematology & Oncology 2023 16:81
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2023 16:76

  27. Tumour-associated macrophages (TAMs) are crucial components of the tumour microenvironment and play a significant role in tumour development and drug resistance by creating an immunosuppressive microenvironmen...

    Authors: Mengyuan Li, Yuhan Yang, Liting Xiong, Ping Jiang, Junjie Wang and Chunxiao Li
    Citation: Journal of Hematology & Oncology 2023 16:80
    Content type: Review Published on:

  28. Third-generation chimeric antigen receptor (CAR)-engineered T cells (CARTs) might improve clinical outcome of patients with B cell malignancies. This is the first report on a third-generation CART dose-escalat...

    Authors: Maria-Luisa Schubert, Anita Schmitt, Angela Hückelhoven-Krauss, Brigitte Neuber, Alexander Kunz, Philip Waldhoff, Dominik Vonficht, Schayan Yousefian, Lea Jopp-Saile, Lei Wang, Felix Korell, Anna Keib, Birgit Michels, Dominik Haas, Tim Sauer, Patrick Derigs…
    Citation: Journal of Hematology & Oncology 2023 16:79
    Content type: Research Published on:

  29. The rapidly increasing use of high-throughput screening had produced a plethora of expanding knowledge on the molecular basis of natural killer/T-cell lymphoma (NKTCL), which in turn has revolutionized the tre...

    Authors: Xiao-Peng Tian, Yi Cao, Jun Cai, Yu-Chen Zhang, Qi-Hua Zou, Jin-Ni Wang, Yu Fang, Jia-Hui Wang, Song-Bin Guo and Qing-Qing Cai
    Citation: Journal of Hematology & Oncology 2023 16:78
    Content type: Review Published on:

  30. The receptor tyrosine kinases TAM family (TYRO3, AXL, and MERTK) are highly expressed in multiple forms of cancer cells and tumor-associated macrophages and promote the development of cancers including pancrea...

    Authors: Jiawei Fan, Ye Yu, Lanzhen Yan, Yuncang Yuan, Bin Sun, Dong Yang, Nan Liu, Jing Guo, Jie Zhang and Xudong Zhao
    Citation: Journal of Hematology & Oncology 2023 16:77
    Content type: Research Published on:

  31. Survival in multiple myeloma has improved significantly in recent years, especially in young patients. We reviewed the evolution of the survival of patients with MM in three groups based on age at MM diagnosis...

    Authors: N. Lopez-Muñoz, G. Hernández-Ibarburu, R. Alonso, J. M. Sanchez-Pina, R. Ayala, M. Calbacho, C. Cuellar, M. T. Cedena, A. Jiménez-Ubieto, R. Iñiguez, M. Pedrera, J. Cruz, L. Meloni, D. Pérez-Rey, P. Serrano, J. de la Cruz…
    Citation: Journal of Hematology & Oncology 2023 16:76
    Content type: Correspondence Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2023 16:81

  32. The mRNA-based therapeutics have become the hot spot of biopharmaceutical industries in recent years. The landscape of this area is expanding from infectious disease to cancer, which needs to be summarized to ...

    Authors: Dawei Wu, Lingfeng Hu, Xin Wang, Yue Yu, Shuo-Peng Jia, Hui-Yao Huang, Zi-Wei Li, Jin-Feng Ma, Hai-Bo Zhu, Yu Tang and Ning Li
    Citation: Journal of Hematology & Oncology 2023 16:75
    Content type: Correspondence Published on:

  33. Early detection and diagnosis of many cancers is very challenging. Late stage detection of a cancer always leads to high mortality rates. It is imperative to develop novel and more sensitive and effective diag...

    Authors: Xiangyi Kong, Peng Gao, Jing Wang, Yi Fang and Kuo Chu Hwang
    Citation: Journal of Hematology & Oncology 2023 16:74
    Content type: Review Published on:

  34. Pevonedistat is a first-in-class, small molecular inhibitor of NEDD8-activating enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Preclinical data suggest s...

    Authors: Nicholas J. Short, Muharrem Muftuoglu, Faustine Ong, Lewis Nasr, Walid Macaron, Guillermo Montalban-Bravo, Yesid Alvarado, Mahesh Basyal, Naval Daver, Courtney D. Dinardo, Gautam Borthakur, Nitin Jain, Maro Ohanian, Elias Jabbour, Ghayas C. Issa, Wei Qiao…
    Citation: Journal of Hematology & Oncology 2023 16:73
    Content type: Research Published on:

  36. Tumor-associated myeloid cells (TAMCs) are among the most important immune cell populations in the tumor microenvironment, and play a significant role on the efficacy of immune checkpoint blockade. Understandi...

    Authors: Xinyu Cheng, Huilan Wang, Zhongyu Wang, Bo Zhu and Haixia Long
    Citation: Journal of Hematology & Oncology 2023 16:71
    Content type: Review Published on:

  37. Multiple myeloma is preceded by monoclonal gammopathy of undetermined significance (MGUS). Serum markers are currently used to stratify MGUS patients into clinical risk groups. A molecular signature predicting...

    Authors: Fumou Sun, Yan Cheng, Jun Ying, David Mery, Samer Al Hadidi, Visanu Wanchai, Eric R. Siegel, Hongwei Xu, Dongzheng Gai, Timothy Cody Ashby, Clyde Bailey, Jin-Ran Chen, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Siegfried Janz…
    Citation: Journal of Hematology & Oncology 2023 16:70
    Content type: Correspondence Published on:

  39. We developed a 13-mer locked nucleic acid (LNA) inhibitor of miR-221 (LNA-i-miR-221) with a full phosphorothioate (PS)-modified backbone. This agent downregulated miR-221, demonstrated anti-tumor activity agai...

    Authors: Pierfrancesco Tassone, Maria Teresa Di Martino, Mariamena Arbitrio, Lucia Fiorillo, Nicoletta Staropoli, Domenico Ciliberto, Alessia Cordua, Francesca Scionti, Bernardo Bertucci, Angela Salvino, Mariangela Lopreiato, Fredrik Thunarf, Onofrio Cuomo, Maria Cristina Zito, Maria Rosanna De Fina, Amelia Brescia…
    Citation: Journal of Hematology & Oncology 2023 16:68
    Content type: Research Published on:

  40. Exosomal circRNA serves a novel genetic information molecule, facilitating communication between tumor cells and microenvironmental cells, such as immune cells, fibroblasts, and other components, thereby regul...

    Authors: Fan Zhang, Jiajia Jiang, Hui Qian, Yongmin Yan and Wenrong Xu
    Citation: Journal of Hematology & Oncology 2023 16:67
    Content type: Review Published on:

  41. Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a poor prognosis. Initial responses to standard-of-care chemo-immunotherapy are, unfortunately, followed by rapid disease recurrence...

    Authors: Charles M. Rudin, Martin Reck, Melissa L. Johnson, Fiona Blackhall, Christine L. Hann, James Chih-Hsin Yang, Julie M. Bailis, Gwyn Bebb, Amanda Goldrick, John Umejiego and Luis Paz-Ares
    Citation: Journal of Hematology & Oncology 2023 16:66
    Content type: Review Published on:

  42. Hematologic malignancies (HMs) pose a serious threat to patients’ health and life, and the five-year overall survival of HMs remains low. The lack of understanding of the pathogenesis and the complex clinical ...

    Authors: Jinxin Li, Qiwei Wang, Yingli Han, Lingli Jiang, Siqi Lu, Beini Wang, Wenchang Qian, Meng Zhu, He Huang and Pengxu Qian
    Citation: Journal of Hematology & Oncology 2023 16:65
    Content type: Review Published on:

  44. Early detection is critical for improving the survival of breast cancer (BC) patients. Exhaled breath testing as a non-invasive technique might help to improve BC detection. However, the breath test accuracy f...

    Authors: Jiaqi Liu, Haibin Chen, Yalun Li, Yanman Fang, Yang Guo, Shuangquan Li, Juan Xu, Ziqi Jia, Jiali Zou, Gang Liu, Hengyi Xu, Tao Wang, Dingyuan Wang, Yiwen Jiang, Yang Wang, Xuejie Tang…
    Citation: Journal of Hematology & Oncology 2023 16:63
    Content type: Correspondence Published on:

  45. The cytotoxicity of NK cells is largely dependent on IgG Fc receptor CD16a, which mediates antibody-dependent cell-mediated cytotoxicity (ADCC). The high-affinity and non-cleavable CD16 (hnCD16) is developed a...

    Authors: Fanyi Meng, Siqi Zhang, Juan Xie, Yuan Zhou, Qingling Wu, Binyan Lu, Shixin Zhou, Xiangyu Zhao and Yang Li
    Citation: Journal of Hematology & Oncology 2023 16:62
    Content type: Research Published on:

  47. B cell maturation antigen (BCMA)-targeted immunotherapy has shown unprecedented results in the treatment of relapsed or refractory (R/R) multiple myeloma (MM). However, disease progression remains an issue att...

    Authors: Jieyun Xia, Zhenyu Li and Kailin Xu
    Citation: Journal of Hematology & Oncology 2023 16:60
    Content type: Correspondence Published on:

  48. Amino acids are basic nutrients for immune cells during organ development, tissue homeostasis, and the immune response. Regarding metabolic reprogramming in the tumor microenvironment, dysregulation of amino a...

    Authors: Luming Yang, Zhaole Chu, Meng Liu, Qiang Zou, Jinyang Li, Qin Liu, Yazhou Wang, Tao Wang, Junyu Xiang and Bin Wang
    Citation: Journal of Hematology & Oncology 2023 16:59
    Content type: Review Published on:

  49. We compared outcomes of adult patients with secondary acute myeloid leukemia (sAML) versus de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) with post-transplant cyclophosphamide ...

    Authors: Arnon Nagler, Myriam Labopin, Didier Blaise, Anna Maria Raiola, Lucia Lopez Corral, Stefania Bramanti, Simona Sica, Mi Kwon, Yener Koc, Jiri Pavlu, Alexander Kulagin, Alessandro Busca, Arancha Bermúdez Rodríguez, Péter Reményi, Christoph Schmid, Eolia Brissot…
    Citation: Journal of Hematology & Oncology 2023 16:58
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2023 16:106

JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2022 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    74 days submission to accept (Median)

    2022 Usage 
    2,836,875 downloads
    9,883 Altmetric mentions 

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us